Additional information
| Active substance | Tolvaptan |
|---|---|
| Chemical name | N-[4-[(5R)-7-chloro-5-hydroxy-2-oxo-3-oxabicyclo[4.3.0]nona-1,6-dien-9-yl]pentyl]-1-methylbenzimidazole-2-carboxamide |
| Side effects | Thirst, dry mouth, nausea, polyuria, hyperglycemia, raised liver enzymes |
| Effects | Increases urine output without affecting the excretion of potassium and sodium, corrects hyponatremia |
| Dosage (sports) | Not applicable as it is not typically used in sports |
| Dosage (medical) | Initial dose of 15 mg once daily, may be increased to a maximum of 60 mg daily based on serum sodium levels and clinical response |
| Half-life | Approximately 12 hours |
| Main action | Vasopressin V2 receptor antagonist |
| Substance class | Benzazepine derivative |
| Formula | C_26H_25ClN_2O_3 |
| Storage conditions | Store at room temperature away from moisture and heat |
| Trade name | Samsca |
| Blood pressure | Generally has minimal effect on blood pressure |
| Also known as | OPC-41061 |
| Strength | 30mg |
| Lab Test | Monitoring of serum sodium levels and liver function tests are necessary |
| Hepatotoxicity | Can cause significant increases in liver enzymes, potential for serious liver injury |
| Water Retention | Reduces water retention by promoting free water excretion |
| Use in sports | None, as it is not known to enhance athletic performance |
| Manufacturer | Centaur Pharmaceuticals Pvt. Ltd |
| Packing | 4 tabs/blister |
Reviews
There are no reviews yet.